ArticleBMC public health2023
Burden of gastroesophageal reflux disease in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of disease study 2019.
Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Pooled it
- Gastrointestinal Symptoms and Systemic Comorbidities in Patients With POTS: A Systematic Review and Meta-Analysis.Neurogastroenterology and motility · 2026Pooled it
- Helicobacter pylori Infection and Eradication in Relation to Gastroesophageal Reflux Disease.Journal of gastroenterology and hepatology · 2025Pooled it
- The relationship between amino acids and gastroesophageal reflux disease: evidence from a mendelian randomization analysis combined with a meta-analysis.Frontiers in immunology · 2025Pooled it
- Endoluminal Procedures and Devices for Esophageal Tract Investigation: A Critical Review.Sensors (Basel, Switzerland) · 2023Pooled it
- Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [Frontiers in pharmacology · 2025Trial
- Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial.Neurogastroenterology and motility · 2025Trial
- Effect of Fermented Soybean (FSB) Supplementation on Gastroesophageal Reflux Disease (GERD).Nutrients · 2024Trial
- Self-management of reflux symptoms after esophagectomy in China: A qualitative study.Asia-Pacific journal of oncology nursing · 2026Article
- Mendel randomization confirmed gastroesophageal reflux disease may increase the risk of mental disorders.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026Article
- Relationship between metabolic syndrome-related parameters and endoscopic classification of gastroesophageal reflux disease: a Japanese health checkup cohort study.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Safety and Efficacy of Fixed-Dose Pantoprazole and Sustained Release Levosulpiride for Short-Term Management of Gastroesophageal Reflux Disease.Gastroenterology research · 2026Article
- Tegoprazan in Gastroesophageal Reflux Disease and Related Acid-Mediated Conditions: A Systematic Review and Meta-Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Perceived stress, diet, and medication use associated with GERD symptoms in Lebanese adults: A cross-sectional study.Journal of public health research · 2026Article
- The global, regional, and national patterns of change in the burden of gastroesophageal reflux disease, 1990-2021: An analysis of the global burden of disease study 2021 and forecast to 2036.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- The impact of gastroesophageal reflux disease in East Asia and China between 1990 and 2021: insights from the 2021 global burden of disease research.BMC gastroenterology · 2026Article
- A Historical and Scientific Review of Anti-Reflux Surgery: Evolution, Evidence, and Future Directions.Current gastroenterology reports · 2026Review
- Ecological co-burden patterns of GERD and asthma: a multi-method analysis of representative global regions.Frontiers in nutrition · 2026Article
- Article
- Trends in the burden of gastroesophageal reflux disease in China and Global from 1990 to 2021 and predictive analysis for 2040.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFor effective preventive strategies against GORD (gastro-esophageal reflux disease), we assessed the GORD burden from 1990 to 2019.
methodsThe burden of GORD between 1990 and 2019 was evaluated globally, regionally, and nationally. Using ASIR (age-standardized incidence), ASYLDs (age-standardized years lived with disabilitys), we compared them to the GBD world population per 100,000. The estimates were based on 95% uncertainty intervals (UIs). The AAPC (average annual percent change) in incidence, YLDs, along with prevalence rates with associated 95% CIs were estimated.
resultsData to estimate the burden of GORD are scarce till now. The global ASIR of GORD in 2019 was 3792.79 per 100,000, an increase AAPC of 0.112% from 1990. The prevalence of GORD increased with a AAPC of 0.096% to 9574.45 per 100,000. Global ASYLDs in 2019 was 73.63, an increase AAPC of 0.105% from 1990. The GORD burden varies greatly depending on the development level and geographical location. USA demonstrated the most obvious decreasing trend in burden of GORD, while Sweden had an increasing trend. That the increase in GORD YLDs was mediated primarily by the growth and aging of population, was revealed by decomposition analyses. There was an inverse relationship between SDI (socio-demographic index) and GORD-burden. Frontier analyses revealed significant scope of improvement in the status of development at all levels.
conclusionGORD is a public health challenge, especially in Latin America. Some SDI quintiles had declining rates, while some countries experienced increased rates. Thus, resources should be allocated for preventative measures based on country-specific estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.